Eye Health News and Research

Latest Eye Health News and Research

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

New book on malaria tells story of Plasmodium falciparum Genome Project

Few infectious diseases can rival malaria's ability to kill and cripple. Each year the disease causes hundreds of millions of people to be sickened and more than a million - mostly African children under the age of five - die.

18 Aug 2012

Pennsylvania Department of Health reports four confirmed and six probable cases of H3N2v flu

The Pennsylvania Department of Health today reported four confirmed and six probable human cases of influenza due to a new strain of the flu known as H3N2v.

18 Aug 2012

Overcorrection is a risk in pediatric exotropia surgery

One-third of pediatric patients treated surgically for intermittent exotropia have excellent post-treatment alignment, and two-thirds have satisfactory control of the condition after the procedure, show UK study results.

17 Aug 2012

Age, drugs, and disease alter sleep in Parkinson’s disease

Sleep patterns in patients with Parkinson’s disease are affected by age, disease severity, and dopamine agonists, German research indicates.

17 Aug 2012

New DNA sequencing tests improve ability to analyze genetic disorders

Scientists at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS) have developed new DNA sequencing tests that hold significant promise for decreasing costs associated with diagnosing cancer and hereditary diseases, including cysticfibrosis.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Scientists devise new fluorescent probes to diagnose neurodegenerative diseases

Sticky plaques of proteins called amyloids mark several different, though related degenerative brain diseases including Alzheimer's, Parkinson's and Creutzfeld-Jacobs. The symptoms of these disorders overlap and methods to diagnose and monitor them are not very advanced.

16 Aug 2012

CYCLOPS genes may serve as targets for cancer therapies

The genomic tumult within tumor cells has provided scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard with clues to an entirely new class of genes that may serve as an Achilles' heel for many forms of cancer.

16 Aug 2012

Novel device provides retina's neural code to restore normal vision

Two researchers at Weill Cornell Medical College have deciphered a mouse's retina's neural code and coupled this information to a novel prosthetic device to restore sight to blind mice.

15 Aug 2012

Ryan's Medicare plan comes under greater scrutiny

As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.

14 Aug 2012

Antisense therapy shows promise in treating toxoplasmosis

A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.

14 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

First Edition: August 13, 2012

Kaiser Health News staff writer Jordan Rau reports: "More than 2,000 hospitals - including some nationally recognized ones - will be penalized by the government starting in October because many of their patients are readmitted soon after discharge, new records show".

13 Aug 2012

Johns Hopkins CIDR receives NIH contract to study genetic diseases

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

13 Aug 2012

Heat wave safety tips from Children's Hospital Los Angeles

With July 2012 on record as being one of the hottest months in U.S. history and the August heat showing no let up in many parts of the country, how can parents protect their children's health during a heat wave? "While kids and teens may think of themselves as invincible, they're prone to heat-related illnesses," says Megan Summers, a registered nurse in the Children's Hospital Los Angeles' Rehabilitation Unit.

12 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Lucentis receives FDA approval for treatment of diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

10 Aug 2012

Molecular missteps disrupt brain function in adult-onset muscular dystrophy

The molecular missteps that disrupt brain function in the most common form of adult-onset muscular dystrophy have been revealed in a new study published by Cell Press. Myotonic dystrophy is marked by progressive muscle wasting and weakness, as well as excessive daytime sleepiness, memory problems, and mental retardation.

10 Aug 2012

Worldwide data reveal gaps in elderly eye care

Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.

10 Aug 2012